The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Nov. 09, 2010
Filed:
Aug. 11, 2006
Daniel Perrissoud, Bad Homburg, DE;
Jean Martinez, Caux, FR;
Aline Moulin, Portes-les-Valence, FR;
Jean-alain Fehrentz, St. Nazaire de Pezan, FR;
Damien Boeglin, Eguisheim, FR;
Luc Demange, Orsay, FR;
Daniel Perrissoud, Bad Homburg, DE;
Jean Martinez, Caux, FR;
Aline Moulin, Portes-les-Valence, FR;
Jean-Alain Fehrentz, St. Nazaire de Pezan, FR;
Damien Boeglin, Eguisheim, FR;
Luc Demange, Orsay, FR;
Zentaris GmbH, Frankfurt, DE;
Le Centre National de la Recherche Scientifique, Paris, FR;
University of Montpellier I, Montpellier, FR;
University of Montpellier II, Montpellier, FR;
Abstract
The present invention provides novel triazole derivatives as ghrelin analogue ligands of growth hormone secretagogue receptors according to formula (I) that are useful in the treatment or prophylaxis of physiological and/or pathophysiological conditions in mammals, preferably humans, that are mediated by GHS receptors. The present invention further provides GHS receptor antagonists and agonists that can be used for modulation of these receptors and are useful for treating above conditions, in particular growth retardation, cachexia, short-, medium- and/or long term regulation of energy balance; short-, medium- and/or long term regulation (stimulation and/or inhibition) of food intake; adipogenesis, adiposity and/or obesity; body weight gain and/or reduction; diabetes, diabetes type I, diabetes type II, tumor cell proliferation; inflammation, inflammatory effects, gastric postoperative ileus, postoperative ileus and/or gastrectomy (ghrelin replacement therapy).